Immedica Acquired by KKR and Impilo in Strategic Move

Deal News | Jan 24, 2025 | CVC Capital Partners

The article announces that CVC Credit, the credit management arm of CVC Capital Partners, has provided debt financing for the acquisition of Immedica Pharma by KKR and Impilo. Immedica, a Swedish pharmaceutical company, focuses on launching and commercializing drugs for rare and specialty diseases and operates in over 50 countries. The company's acquired capabilities span various pharmaceutical sectors, including marketing, sales, and pharmacovigilance. CVC Credit highlights Immedica’s profitable growth trajectory since its inception in 2018 and expresses eagerness to support its future expansion.

Sectors

  • Pharmaceuticals
  • Investment Management

Geography

  • Sweden – Immedica Pharma is headquartered in Stockholm, Sweden.
  • Global – Immedica operates a distribution network reaching over 50 countries worldwide.

Industry

  • Pharmaceuticals – Immedica operates in the pharmaceutical sector, specializing in rare and specialty diseases.
  • Investment Management – KKR and Impilo represent firms significant in private equity and investment management.

Financials

  • 41 billion – The size of CVC's global credit management business.

Participants

NameRoleTypeDescription
Immedica PharmaTarget CompanyCompanyA Swedish pharmaceutical company focusing on drugs for rare and specialty diseases.
KKRBidding CompanyCompanyA global investment firm involved in the acquisition of Immedica Pharma.
ImpiloBidding CompanyCompanyA Nordic healthcare investment firm partaking in the acquisition of Immedica Pharma.
CVC CreditDebt ProviderCompanyThe credit management arm of CVC Capital Partners providing debt facilities for the acquisition.
CVC Capital PartnersCredit ManagementCompanyAn international private equity and investment advisory firm.
Moris NachmiasManaging DirectorPersonA Managing Director at CVC Credit commenting on the acquisition.